Examkin

Soru

Zorluk: OrtaMonitoring and Treatment Evaluation

A 2222-year-old man with type 1 diabetes mellitus is being treated in the intensive care unit for diabetic ketoacidosis. He has been receiving a continuous intravenous regular insulin infusion, intravenous fluids, and potassium replacement for the past 1414 hours. Current laboratory evaluation reveals a blood glucose of 178178 mg/dL, a serum bicarbonate of 2020 mEq/L, and a calculated anion gap of 99 mEq/L. The patient is awake, alert, and reports feeling hungry. The physician decides to transition the patient to a subcutaneous insulin regimen. Arrange the following management and monitoring steps in the correct chronological sequence to safely accomplish this therapeutic de-escalation.

  1. 1Verify biochemical resolution of ketoacidosis and confirm the patient can tolerate oral intake
  2. 2Administer a dose of subcutaneous long-acting basal insulin
  3. 3Continue the continuous intravenous regular insulin infusion for an overlapping period of 11 to 22 hours
  4. 4Discontinue the continuous intravenous regular insulin infusion
  5. 5Implement routine point-of-care blood glucose monitoring before meals and at bedtime

Cevap

The correct sequence begins with verifying diabetic ketoacidosis resolution, followed by administering subcutaneous basal insulin, maintaining an overlap with the intravenous insulin for 11 to 22 hours, discontinuing the intravenous infusion, and finally initiating routine preprandial monitoring.
The successful treatment of diabetic ketoacidosis requires a carefully monitored transition from continuous intravenous insulin to intermittent subcutaneous insulin. The protocol dictates that the physician must first confirm resolution of the ketoacidosis (anion gap ≤12\leq 12 mEq/L) and ensure the patient can tolerate oral intake. Because intravenous insulin clears the body within minutes and subcutaneous insulin takes 11 to 22 hours to begin working, subcutaneous basal insulin must be administered while the intravenous infusion is still running. This 11 to 22 hour overlap is critical to prevent a gap in insulin coverage, which would cause rapid rebound ketoacidosis. Only after this overlap period is complete should the intravenous infusion be discontinued. Finally, the patient is transitioned to routine maintenance monitoring, typically involving blood glucose checks before meals and at bedtime.

Adım Adım Çözüm

1
Assess clinical and laboratory criteria for diabetic ketoacidosis resolution.
The anion gap is closed (99 mEq/L) and the patient is able to eat.
Ensures that transitioning off continuous insulin is safe and physiologically appropriate.
2
Administer subcutaneous long-acting basal insulin.
A long-acting insulin depot is established in the subcutaneous tissue.
Provides baseline insulin coverage to prevent rebound hyperglycemia.
3
Overlap the intravenous and subcutaneous insulin for 11 to 22 hours.
Continuous insulin coverage is maintained during subcutaneous absorption.
Subcutaneous insulin takes time to reach systemic circulation and take effect.
4
Stop the continuous intravenous regular insulin infusion.
The patient is completely transitioned to subcutaneous insulin.
Intravenous insulin is no longer needed once the subcutaneous depot is active.
5
Transition to standard inpatient glycemic monitoring.
Blood glucose is checked before meals and at bedtime.
Allows for ongoing monitoring and administration of short-acting nutritional/correctional insulin.

Anahtar Kavram

Therapeutic De-escalation Protocol for Diabetic Ketoacidosis
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru